Video

Our team behind the scenes at SXSW | Opening by Joanna Shields, BenevolentAI CEO

In our 5 part series filmed at SXSW, our team showcased how AI can be used to better understand the underlying causes of disease, and redefine the way new medicines are brought to patients.

In this first video, our CEO, Joanna Shields, introduces the Benevolent team and our vision. We brought our Benevolent Team to Texas to share our collective vision of using the power of technology to solve something that truly matters to the world. For us, this means tackling the most challenging and devastating diseases that currently have no cure. We believe our efforts can and will change outcomes for patients.

There are an estimated 9,000 untreated diseases in the world and 300 million people suffering from rare diseases. Developing a treatment and getting it to market takes 10-15 years and costs more than $2.5 billion. After all that, the top ten selling drugs in the market today only work for 30-50% of patients.

Why? Because biology is complicated. The underlying molecular mechanisms, pathways and biological processes specific to a patient needs to be fully understood to effectively diagnose a disease and develop a medicine to treat it.

Humans are limited by the amount of information they can absorb and process. Against a backdrop of >10,000 new scientific papers published daily, and the millions of patents, chemical databases, clinical trials and countless other data sources, it’s almost impossible for scientists to leverage all the existing information to make new discoveries.  While this deluge of data represents a limitation of human comprehension, it lends itself perfectly to machine learning.  

AI can help us uncover relationships between diseases and symptoms, drugs and their effect, the patients that will best respond to treatment and much more. At BenevolentAI, we believe that unconventional thinking combined with purposeful technology can truly make an impact on humanity.  

Watch our team share this example of how we work to do exactly that.

More Posts

You Might Also Like

News
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
Sep 14, 2020
Blog
Building the next generation of leaders with Circl
BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.
Aug 21, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Video
How do we get the next 10 years right? w/ Joanna Shields, CogX
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Blog
Kindness matters: mental health and wellbeing through COVID-19 and beyond
To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.
May 27, 2020